EGL-002

N/A

Report date: 2025/12/08 13:43:22

Base Information

Drug NameEGL-002

Drug Alias NameEGL-002

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-C-C chemokine receptor type 8Anti-IL2RA

TargetsC-C chemokine receptor type 8Interleukin-2 receptor alpha chain

Therapy Area/IndicationsAutoimmune DiseasesNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEgle Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesEgle Therapeutics

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A